150
Participants
Start Date
April 1, 2017
Primary Completion Date
February 28, 2021
Study Completion Date
December 30, 2022
Nivolumab
The normal clinical treatment-plan of the underlying disease remains unchanged.
Pembrolizumab
The normal clinical treatment-plan of the underlying disease remains unchanged.
Radiotherapy
The normal clinical treatment-plan of the underlying disease remains unchanged.
Ipilimumab
The normal clinical treatment-plan of the underlying disease remains unchanged.
Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen
University of Erlangen-Nürnberg Medical School
OTHER